motifs favor farnesylation, by farnesyltransferase (FTase), when X is a Ser, Gln, Met or Ala residue but geranylgeranylgeranylation, by geranylgeranyltransferase I (GGTase-I), when X is a Leu residue (Zhang and Casey, 1996) . X-ray crystallography (Reid et al., 2004) has recently provided a mechanistic basis for the observed specificity of amino acid residues at the A 2 position and their contribution to the overall reactivity of the CAAX-box substrates. These studies indicate that the A 2 position can influence substrate selectivity by FTase and GGTase-I. Therefore, in the case of the lamin proteins, it is noteworthy that Ile or Val at the A 2 position is equally accepted by FTase and GGTase-I. The human lamin CAAX boxes are CSIM for prelamin A, CAIM for mammalian lamin B 1 and CYVM for lamin B 2 . The preference for lamin farnesylation, over geranylgeranylation, thus derives entirely from the C-terminal Met residue. Sequences upstream of the CAAX box, as well as the A 1 residue, have the potential to alter the K m for the protein substrate but are not mechanistic determinants of the specificity of prenylation. There are examples in which CAAX-motif prenylation occurs when the A 1 residue is not aliphatic (e.g. Gln in the case of Rap-1B and Tyr in the case of lamin B 2 ).
All of the above considerations strongly predict that the lamin proteins, including the mutant lamin A proteins found in the various laminopathies, as well as HGPS, should be farnesylated, and further processed at the lamin A CSIM motif. As shown in Fig. 1 , CAAX-box proteins undergo endopeptidase cleavage of the -AAX residues (step B) after farnesylation followed by carboxymethylation (step C) (Zhang and Casey, 1996) . The B endopeptidase activity in step B can be shown for two enzymes: Rce1 (Ras-converting enzyme 1) (Boyartchuk et al., 1997) and Zmpste24 (Zinc metalloprotease related to Ste24p) (Corrigan et al., 2005; Leung et al., 2001 ). The carboxymethylation is catalyzed by the enzyme isoprenylcysteine carboxyl methyltransferase (Icmt) (Winter-Vann and Casey, 2005) .
Biochemical studies on the endoproteolytic maturation of prelamin A
The initial characterization of the processing pathway of prelamin A presented some challenges. Early work by Gerace and co workers (Gerace et al., 1984) had demonstrated the likelihood of a higher molecular-weight precursor for lamin A. Later protein-sequencing studies by Weber on the mature lamin A molecule (Weber et al., 1989) , coupled with comparison to the prelamin A sequence predicted from its cDNA, demonstrated that lamin A undergoes the loss of 18 amino acid residues from the C-terminus during the formation of mature lamin A, which terminates in a Tyr residue. Metabolic radiolabeling and pulse-chase studies with mevalonate demonstrated likely prenylation of prelamin A and a requirement for the putative prenylation for further maturation of the protein .
The transient nature of prelamin A does not allow accumulation of sufficient material for one to characterize the putative isoprenoid by mass-spectrometry. Radiolabeling of the polyisoprenoid with mevalonate is also difficult because of the poor uptake of mevalonate by most cells. The problem of obtaining enough radio-labeled material to characterize, was eventually solved by the use of inducible prelamin A constructs expressed in a cell line with an activated mevalonate transporter (Faust and Krieger, 1987) . Characterization of the prelamin A poly-isoprenoid substituent as farnesyl could then proceed through the same Raney-nickel cleavage method that had been successfully employed for lamin B 1 but utilizing co chromatography on GLC with synthetic standards and in-line radiodetection to identify the product as being derived from farnesyl thioether.
The inducible prelamin A constructs were utilized to verify carboxymethylation of prelamin A (Sinensky et al., 1994) . Since carboxymethylation can only occur after endoproteolysis, this was consistent with prelamin processing proceeding through the canonical CAAX-box processing pathway (Fig. 1) . In vitro studies with recombinant enzymes directly demonstrate that both Rce 1 or Zmpste24 can use prelamin A as a substrate in step B (Corrigan et al., 2005) .
In vitro studies with a model polypeptide, as well as studies on CAAX-box mutants expressed in cells (Kilic et al., 1997) , showed that a farnesylated, carboxymethylated prelamin A is the required substrate for a final endoproteolytic cleavage after Tyr646 (step D in Fig. 1 ) by an enzyme that recognizes a conserved hexapeptide cleavage motif RSYfLLG, and gives rise to mature lamin A. No other farnesylated mammalian protein is known to undergo a second, upstream endoproteolysis, and the highly conserved cleavage sequence is unique to prelamin A in vertebrate protein sequence databases, even allowing for conserved substitutions (Kilic et al., 1997) . Thus, the second endoproteolysis currently appears to be unique to prelamin A processing.
In vitro studies with recombinant Zmpste24 and a recombinant fragment of prelamin A demonstrated that Zmpste24 has step D endoprotease activity (Corrigan et al., 2005) . In vivo studies (data not shown) indicate that Zmpste24 is not essential for the first endoproteolytic cleavage, which can also be performed by Rce1, but is essential for the second (our unpublished data).
Genetic studies on farnesylation-dependent lamin maturation Knockout studies, in fact, first suggested that Zmpste24 is the step D endoprotease. As mentioned above, farnesylation was first studied in fungal pheromones, particularly Saccharomyces a-factor. This polypeptide, like prelamin A, undergoes Nterminal endoproteolysis during maturation, which is mediated by two enzymes: Ste24p and Ste23p. Discovery of a mammalian orthologue of Ste24p, Zmpste24, suggested that Zmpste24 plays a similar role in prenylation-dependent posttranslational processing in mammalian cells . Zmpste24-knockout mice (Bergo et al., 2002; Pendas et al., 2002) accumulate prelamin A, and the later biochemical studies (Corrigan et al., 2005) showed that Zmpste24 can mediate both of the endoproteolytic steps in prelamin A maturation.
In mouse embryo fibroblasts lacking Icmt or Rce1 (but not those lacking Zmpste24) a fluorescent construct expressing the 40 C-terminal residues of lamin B 1 is mislocalized and the nuclear lamina has structural defects (Maske et al., 2003) . The apparent lack of activity of Zmpste24 in B-lamin processing is surprising because the yeast orthologues appear to have overlapping substrate specificities (Trueblood et al., 2000) . Notice, however, that the Rce1 and Icmt knockouts will have defective processing of numerous farnesylated and geranylgeranylated proteins, which could disrupt lamina structure indirectly.
Farnesylation, prelamin A and progeria 3267
Prenylated proteins, membranes and farnesylated lamins Biophysical studies using model farnesylated and carboxymethylated peptides indicate that farnesylated proteins should be predominantly, but not entirely, membrane associated (Silvius and l'Heureux, 1994) . The hydrophobic contribution of carboxymethylation is also significant and a substantial fraction of a protein modified only by a farnesyl group would not be expected to be associated with membranes. Even with both farnesylation and methylation, the dissociation constants of peptides from lipid bilayers can vary from 10 fM to several hundred micromolar, depending on the bilayer composition. Thus, CAAX-box-mediated association with membrane bilayers is inherently reversible. Stable membrane association of a farnesylated protein (e.g. Ras) requires a second lipid-bilayer-binding moiety (Hancock et al., 1990; Schroeder et al., 1997; Shahinian and Silvius, 1995) . For Ras proteins, this is either palmitoylation (N-Ras and H-Ras) or a polybasic domain (K-Ras). Both carboxymethylation and palmitoylation are chemically reversible modifications, making it theoretically feasible to dissociate even doubly modified proteins from membranes. In the case of Ras proteins, both palmitoylation status and subcellular localization are highly dynamic (Magee and Seabra, 2005) .
This reversibility of membrane association of farnesylated proteins is consistent with the hypothesis that CAAX modifications, in addition to targeting proteins to membranes, also facilitate protein-protein interactions. Indeed, there is considerable evidence that this is the case (Basso et al., 2006; Sinensky, 2000; Zhang and Casey, 1996) .
Prelamin A mutants that cannot be processed at step D by Zmpste24 (Corrigan et al., 2005; Hennekes and Nigg, 1994; Mallampalli et al., 2005) are localized to the nuclear membrane. Since these mutants are expected to be farnesylated and carboxymethylated, these observations support a role for these CAAX modifications of prelamin A in nuclear membrane targeting (Nigg et al., 1992) . Similar observations exist for B lamins. Mutations of the lamin B 1 (Mical and Monteiro, 1998) or lamin B 2 (Kitten and Nigg, 1991) CAAX box that block prenylation, also block incorporation of the lamin B proteins into the nuclear envelope, leading to their accumulation in the nucleoplasm. Lamin proteins do not have secondary lipidbilayer-binding regions analogous to those of the Ras proteins. Membrane association of prenylated lamin proteins might therefore be stabilized by their binding to a membrane receptor, and a body of evidence supports binding of lamin B 1 to a lamin B receptor (Smith and Blobel, 1994; Worman et al., 1990; Worman et al., 1988) . The binding site appears to map to the C-terminus of the B-lamins (Dreger et al., 2002; Maske et al., 2003) .
Since the CAAX-motif modifications of the B-lamins are typical of CAAX proteins, their role as mediators of nuclear envelope association has a strong rationale. By contrast, the functional significance of prelamin A processing, in which the farnesylated and carboxymethylated C-terminal peptide is ultimately removed, is unknown and intriguing. It is clearly not required for assembly of lamin A into the lamina -this has been shown by expression studies of the mature protein (Lutz et al., 1992) and, of course, mature lamin A is disassembled and reassembled into the lamina routinely during the course of mitosis (Gerace et al., 1984) . However, mutations or reagents that block farnesylation, thereby preventing removal of the Cterminal 18 residues of prelamin A, block its incorporation into the lamina (Holtz et al., 1989; Lutz et al., 1992; Sasseville and Raymond, 1995) , which suggests that the sequence inhibits this.
One hypothesis is that farnesylated and carboxymethylated prelamin A has a distinct function and that the processing pathway regulates its levels. In this regard, yeast two-hybrid studies have revealed a specific binding partner of farnesylated prelamin A: Narf (Barton and Worman, 1999) . The function of Narf is unknown. However, epitope-tagged Narf localizes to both the nuclear envelope and the nucleoplasm, which suggests it interacts with farnesylated and carboxymethylated prelamin A in both locations.
RD and HGPS: diseases of prelamin A maturation
In both RD and HGPS, there is strong circumstantial evidence that step D of the prelamin A maturation pathway is defective, and we have confirmed this chemically (unpublished data).
RD (OMIM: 275210) is a neonatally fatal autosomal recessive disease that arises from homozygous loss of expression of Zmpste24 (Levy et al., 2005; Moulson et al., 2005; Navarro et al., 2005; Navarro et al., 2004) . It is characterized by very tight, thin easily eroded skin, rockerbottom feet and joint contractures. In addition, prelamin A accumulates in cells from RD patients Navarro et al., 2005) .
HGPS is a complex autosomal dominant disease (OMIM: 176660) that arises from a mutation in the prelamin A gene that leads to low-level expression of a prelamin A mRNA (L150 LMNA) that has a deletion of 150 bp of exon 11 arising from a variably used new splice site (Eriksson et al., 2003) . L150 LMNA constitutes approximately 40% of the transcripts found in cells from HGPS patients (Reddel and Weiss, 2004) . This mutant mRNA encodes a protein (known as LAL50 or progerin) that has an in-frame deletion of 50 amino acid residues of the prelamin A sequence. Progerin can readily be separated from wild-type prelamin A and lamin A on SDS PAGE and visualized by anti-lamin-A antibody Pollex and Hegele, 2004) . The predicted amino acid sequence of progerin (Eriksson et al., 2003) is missing the sequence necessary for step D, RSYfLLG, which is consistent with the hypothesis that there is a block in maturation at this step (Fig. 2) . Progerin, as is the case for artificially generated
Step-D-resistant mutants, localizes to the nuclear envelope (Goldman et al., 2004) .
Patients with HGPS exhibit physical features reminiscent of aging, including bone fragility, loss of hair and lipodystrophy (Pollex and Hegele, 2004) . They also have extensive vascular problems, which lead to premature atherosclerosis and stroke, common causes of death Ha et al., 1993; McClintock et al., 2006) . Cells from HGPS patients senesce prematurely in culture (Liu et al., 2005; Wallis et al., 2004 ). This appears to arise from DNA-repair defects, which results in accumulation of DNA double-strand breaks and p53 activation (Liu et al., 2005) . Similar events are associated with senescence of cultured human cells and cells from aging mice (Sedelnikova et al., 2004) . HGPS may thus, at least in some respects, reflect normal aging. Indeed, it has recently been reported (Scaffidi and Misteli, 2006 ) that progerin accumulates in tissues from aged individuals. Homozygous loss of Zmpste24 in RD should also result in the generation of a farnesylated and carboxymethylated prelamin A, Rce1 performing the first endoproteolysis. No wild-type lamin A is produced in this case (Toth et al., 2005) . A compound-heterozygous loss-of-function of Zmpste24 (OMIM: 608612) causes mandibuloacral dysplasia characterized by 'skeletal abnormalities including hypoplasia of the mandible and clavicles, acro-osteolysis, cutaneous atrophy and lipodystrophy' (Agarwal et al., 2003) . This condition might reflect incomplete loss of Zmpste24, because the neonate is viable. Mouse embryo fibroblasts from Zmpste24 -/-mice show the same molecular and cellular characteristics of premature senescence similar to those seen in patients with HGPS (Liu et al., 2005; Varela et al., 2005) . Farnesylated, carboxymethylated prelamin is associated with the nuclear membrane, including invaginations of this membrane into the nucleus (Holtz et al., 1989; Moulson et al., 2005; Toth et al., 2005) . By contrast, non prenylated CAAX-box cysteine mutants of prelamin A accumulate in nucleoplasmic aggregates (Capell et al., 2005; Holtz et al., 1989; Lutz et al., 1992) , which are not membrane associated (Fig. 3) .
Farnesyl transferase inhibitors, lamin maturation and HGPS
Shortly after lamin proteins were shown to be farnesylated, the mammalian Ras proteins were shown to be similarly modified (Casey et al., 1989; Leonard et al., 1990) . A body of yeast genetic studies (Goodman et al., 1990; Powers et al., 1986; Schafer et al., 1990) had previously suggested that posttranslational modification of Ras was required for its signaling and subsequent work showed Ras farnesylation is required for the transforming activity of oncogenic Ras mutants (Casey et al., 1989; Hancock et al., 1989; Schafer et al., 1989) . This raised the possibility that inhibitors of farnesyl transferase (FTIs) could be used in the treatment of cancer. A number of such compounds were developed, and their current status has recently been reviewed (Basso et al., 2006) . Surprisingly, studies from several laboratories revealed that although the prenylation, maturation and function of H-Ras are inhibited by the FTIs, this is not the case for N-Ras and K-Ras (Fiordalisi et al., 2003; James et al., 1996; Rowell et al., 1997; Whyte et al., 1997) . The explanation is that they become geranylgeranylated in the presence of FTIs. This is because of the kinetic basis of specificity towards CAAX substrates of FTase and GGTase1. In the case of K-Ras, there is an ~400 fold higher K m for K-Ras for GGTase 1 compared with FTase (Roskoski, Jr and Ritchie, 1998; Zhang et al., 1997) . However, the k cat values for the two enzymes for K-Ras are virtually identical. Thus, at high cellular levels of non-prenylated K-Ras, as would be the case when farnesylation is blocked, geranylgeranylation by GGTase1 can occur (James et al., 1995) . By contrast, GGTase1 exhibits not only a higher K m for H-Ras than does FTase but the k cat is >100 times lower, which accounts for the effectiveness of FTIs in blocking H-Ras prenylation. Signaling, including oncogenic signaling, by mutant K-Ras (Kato et al., 1992) , and by implication N-Ras, can be supported by geranylgeranylation.
These observations should sound a cautionary note on how biological readouts can be overinterpreted in explanations of biochemical events. FTIs can, indeed, block the growth of numerous N-Ras-and K-Ras-transformed cells in soft agar, nude mice or transgenic mouse models (End et al., 2001; Liu et al., 1999; Nagasu et al., 1995; Omer et al., 2000) . They just do not necessarily do it by affecting the prenylation of the Ras proteins. Other farnesylated proteins have been implicated in the antitumor activity of FTIs (Basso et al., 2006) FTIs have also been proposed as a treatment for HGPS. RD is not a candidate for treatment since it is neonatally lethal. The rationale for such an approach is that the pathological phenotypes seen in HGPS arise from a farnesylated, mutant prelamin A and that inhibition of its farnesylation might reverse these phenotypes. Encouragingly, the blebs that have been observed in the nuclear membranes of cultured fibroblasts from patients with HGPS can be eliminated by treatment with FTIs (Capell et al., 2005; Glynn and Glover, 2005; Mallampalli et al., 2005; Toth et al., 2005) . Although, at this time, no direct demonstration of the farnesylation of progerin has been reported, mevalonate labeling studies by one laboratory (Glynn and Glover, 2005) are certainly consistent with this prediction. The loss of mevalonate labeling of progerin upon treatment of HGPS cells with an FTI is also consistent with inhibition of farnesylation but can be misleading (see below).
FTI treatment has been shown to ameliorate the pathology exhibited by Zmpste24 -/-mice (Fong et al., 2006) although the responses vary depending on the defect. For example, the effects of treatment on the mice are very dramatic in the case of reduction of rib fractures but less so in the case of growth (as measured by body weight). Although there are structural differences between progerin and the prelamin A molecule that accumumulates in the absence of Zmpste24, there are obviously shared structural features, especially the farnesylated and carboxymethylated C-terminal cysteine residue. Thus, these results are consistent with the concept that FTIs could be useful in the treatment of HGPS.
Examining the effects of the FTI BZA-5B, on prelamin A maturation in CHO-K1 cells expressing an activated mevalonate transporter, we observed specific inhibition of protein farnesylation. Considering one recent database search revealed ~70 potential farnesylated proteins (Fiordalisi et al., 2003) , it was surprising that growth of CHO K1 and HeLa cells is not inhibited by treatment with BZA-5B. Although prelamin A accumulates, its processing still occurs, as does assembly of lamin A and lamin B into the nuclear lamina. Farnesylation-dependent protein processing appears to occur even in the absence of detectable farnesylation. The lack of mevalonate labeling of N-Ras, lamin B 1 or prelamin A in these cells in the presence of BZA-5B was not consistent with processing by alternative prenylation. Other work, however, has suggested that mevalonate labeling of geranylgeranylated CAAX proteins can be difficult to detect (Kato et al., 1992; Vestal et al., 1996) . Furthermore, in vitro studies on the prenylation of lamin A and lamin B CAAX polypeptides (Moores et al., 1991) demonstrate that both can be a substrate for GGTase 1, as do studies of in vitro translated prelamin A mRNA (our unpublished data). Expression of prelamin A containing a CVLL geranylgeranylation CAAX box in mammalian cells results in a geranylgeranylated protein that is processed to mature lamin A, albeit inefficiently, such that prelamin A accumulates (Kilic et al., 1997) .
FTI treatment could result in inefficient processing of prelamin A at two steps. Since the K m of GGTase 1 for the prelamin A CAAX of should be considerably higher than that of FTase, non-prenylated prelamin A should accumulate; since the K m of Zmpste24 for the geranylgeranylated prelamin A is higher than for farnesylated prelamin A, the geranylgeranylated precursor might accumulate as well. Prelamin A has been detected with specific anti-prelamin-A antibody in patients treated with FTIs (Adjei, 2003) , but the prenylation status of the accumulated protein was not determined.
Thus, those investigating treatment of HGPS with FTIs face the same questions that concern investigators developing them for treatment of malignancy. (1) Given the spectrum of farnesylated proteins, can FTIs be relied upon to target the protein of interest specifically? (2) Can alternative prenylation produce sufficient levels of biologically active prenylated protein to result in inadequate reversal of the pathological phenotype? As in the case of the Ras proteins, these issues are exacerbated by the desirability of blocking farnesylation of the mutant protein but not the wild-type.
Possible methods for characterization of progerin in cells treated with FTIs
Could progerin become a substrate for GGTase 1 in the presence of an FTI? This seems quite possible and it certainly should be tested if these compounds are to be considered for use in the treatment of HGPS. In our hands, characterization of progerin by mass spectrometry does not give information on the putative farnesylated and carboxymethylated Cterminal cysteine residue. Since this is generally done after trypsin digestion of the sample protein, the peptide fragment expected from progerin is larger than that produced from normal human prelamin A (Fig. 2) (Corrigan et al., 2005) . The reasons it has not been detected are not immediately obvious.
Alternative methods for analysis of the polyisoprenoid substituents include labeling of the polyisoprenoids with mevalonate followed by radiochemical analysis of the cleavage product . As mentioned above, labeling of prenylated proteins with mevalonate is greatly facilitated by using cell lines that express an activated mevalonate transporter (Faust and Krieger, 1987; Whyte et al., 1997) and incubating cells with lovastatin to block endogenous mevalonate biosynthesis. High-specific activity [ 3 H]mevalonate is incorporated into proteins either as farnesyl or geranylgeranyl substituents. These can be released by cleavage of the thioether linkage by either Raney nickel to yield the corresponding alkenes or methyl iodide to yield the corresponding alcohols (Casey et al., 1989) . The alkenes are best resolved by GLC; the alcohols are best resolved by reverse-phase HPLC. The latter has the advantage of not requiring in-line radiodetection if this apparatus is not available. Specific labeling of farnesylated proteins can also be achieved with tritiated farnesol (Andres et al., 1999) .
Another useful method, which gives an indirect measurement of the extent of prenylation but not the polyisoprenoid specificity, is a base-release assay of the prenylated protein after labeling of the lamin protein with [tritiated CH 3 ]-methionine. This method has been successfully applied to the lamin proteins (Chelsky et al., 1987; . Typically, the results are normalized with respect to the total incorporation of the methionine into protein relative to the number of methionines, and compared with lamin B 1 for a theoretical 100% CAAX-modification. This methodology should also be useful for evaluation of alternative processing because a true block to prenylation would also block carboxymethylation.
A recent novel approach to determining farnesylation has been described by Spielmann, Andres and colleagues (Troutman et al., 2005) . They grow cells in medium supplemented with the farnesol analogue anilinogeraniol. This compound incorporates into proteins in place of farnesol, and its incorporation can be measured by antibodies directed against S-anilinogeranyl cysteine methyl ester. This technique is particularly directed at demonstrating the action of an FTI, because the signal would disappear upon FTI treatment. It would not, however, detect alternative prenylation because that would not be distinguishable from the absence of prenylation. However, it could be combined with another method that tests for whether prenylation occurs in the presence of the FTI.
Conclusions and perspectives
To the cell biologist, the most interesting aspect of the lamin CAAX-box post-translational modifications is their functional significance. As pointed out above, these modifications generally seem to function to create reversible membrane associations and heterodimeric protein-protein interactions. The B-lamins appear to represent examples of this common behavior of farnesylated proteins.
The functional role of the CAAX-box modification of prelamin A is, by contrast, quite puzzling, because it is eliminated during the course of prelamin A maturation and thus unique among mammalian CAAX proteins. In the dominant progeroid syndrome, HGPS, prelamin A accumulates to only very low levels and wild-type lamin A levels are not dramatically affected. Prelamin A itself may thus have a functional role and Zmpste24 could serve to regulate its levels. That cellular senescence accompanies accumulation of farnesylated prelamin A in HGPS and RD may provide a clue to that function.
These considerations should stimulate further investigation into the role of farnesylation in the function of prelamin A. The idea that inhibition of prelamin A farnesylation is a potential therapeutic approach, warrants further biochemical analysis of the effects of FTIs on post-translational modification not only of progerin but also of prelamin A and the B-lamins.
